Your browser version may not work well with NCBI's Web applications. More information here...

Recent Activity

Items 1 - 20 of 136
of 7Next
1:

Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting.

Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Watcharananan S, Sathapatayavongs B.

AIDS Res Ther. 2007 Nov 21;4:26.

PMID: 18031583 [PubMed]

2:

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.

MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M; CPCRA 058 Study Team; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

Lancet. 2006 Dec 16;368(9553):2125-35.

PMID: 17174704 [PubMed - indexed for MEDLINE]

3:

HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.

Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B.

Int J STD AIDS. 2007 Dec;18(12):832-4.

PMID: 18073016 [PubMed - indexed for MEDLINE]

4:

Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.

Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.

Clin Infect Dis. 2005 Nov 1;41(9):1326-32. Epub 2005 Sep 29.

PMID: 16206110 [PubMed - indexed for MEDLINE]

5:

Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.

Cuzin L, Pugliese P, Bugnon F, Delpierre C, Cua E, Billaud E, Massip P, Raffi F, Dellamonica P.

HIV Med. 2005 Nov;6(6):388-95.

PMID: 16268820 [PubMed - indexed for MEDLINE]

6:

HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.

Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Touré S, Divi N, Anglaret X, Goldie SJ, Freedberg KA; CEPAC International Investigators.

AIDS. 2007 May 11;21(8):973-82.

PMID: 17457091 [PubMed - indexed for MEDLINE]

7:

API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.

Gupta SB, Pujari SN, Joshi SR, Patel AK; AIDS Society of India Guidelines Development Committee.

J Assoc Physicians India. 2006 Jan;54:57-74. Review.

PMID: 16649742 [PubMed - indexed for MEDLINE]

8:

A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients.

Mallolas J, Blanco JL, Pich J, Arnaiz JA, Peña JM, Dalmau D, de Lazzari E, Ochoa A, Vidal F, Ribas MA, Segura F, Pedrol E, Flores J, Cruceta A, Varea S, Miró JM, Martínez E, Gatell JM.

Rev Clin Esp. 2007 Oct;207(9):427-32.

PMID: 17915162 [PubMed - indexed for MEDLINE]

9:

[Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment]

Pavie J, Porcher R, Fournier S, André F, Tournoux C, Palmer P, Rabian C, Jean-Michel M.

Presse Med. 2005 Jun 4;34(10 Suppl):1S8-13. French.

PMID: 16025661 [PubMed - indexed for MEDLINE]

10:

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, Margolis DM; AIDS Clinical Trials Group 5170 Study Team.

J Infect Dis. 2007 May 15;195(10):1426-36. Epub 2007 Apr 6.

PMID: 17436222 [PubMed - indexed for MEDLINE]

11:

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93.

PMID: 17693883 [PubMed - indexed for MEDLINE]

12:

Improved Measures of Quality of Life, Lipid Profile, and Lipoatrophy After Treatment Interruption in HIV-Infected Patients With Immune Preservation: Results of ACTG 5170.

Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM; the A5170 Study Team.

J Acquir Immune Defic Syndr. 2008 Oct 16. [Epub ahead of print]

PMID: 18931631 [PubMed - as supplied by publisher]

13:

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52. Epub 2006 Dec 27.

PMID: 17205457 [PubMed - indexed for MEDLINE]

14:

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA; California Collaborative Treatment Group.

AIDS. 2002 Oct 18;16(15):F33-40.

PMID: 12370520 [PubMed - indexed for MEDLINE]

15:

Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.

Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F.

Clin Ther. 2007 Jul;29(7):1448-55.

PMID: 17825696 [PubMed - indexed for MEDLINE]

16:

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73. Summary for patients in: Ann Intern Med. 2007 Apr 17;146(8):I28.

PMID: 17438315 [PubMed - indexed for MEDLINE]

17:

Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.

Samri A, Goodall R, Burton C, Imami N, Pantaleo G, Kelleher A, Poli G, Gotch F, Autran B.

Antivir Ther. 2007;12(4):553-8.

PMID: 17668564 [PubMed - indexed for MEDLINE]

18:

Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure.

Gange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R.

J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):68-74.

PMID: 16340476 [PubMed - indexed for MEDLINE]

19:

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.

Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM.

AIDS. 1999 Apr 16;13(6):F35-43.

PMID: 10397555 [PubMed - indexed for MEDLINE]

20:

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID: 15532140 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 136
of 7Next